Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation
IntroductionCDK4/6 inhibitors are the first-line treatment for HR+/HER2- advanced breast cancer. Despite their clinical benefit, they can increase healthcare expenditure. To date, there is no thorough comparison among the three approved CDK4/6 inhibitors in terms of their cost-effectiveness.Objectiv...
Gardado en:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Media S.A.
2024-07-01
|
| Series: | Frontiers in Oncology |
| Assuntos: | |
| Acceso en liña: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1413676/full |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|